Search Results - "Tacar, Seher Yıldız"

Ribociclib induced acute kidney injury: A case report by Gulturk, Ilkay, Yilmaz, Mesut, Ozmen, Aykut, Tacar, Seher Yıldız, Erdal, Gülçin Sahingoz, Tural, Deniz

“…Introduction Among females, breast cancer is the most common type of cancer. Hormon receptor positive (HR+) subtype constitutes 75% of the diagnosed breast…”
Get full text

PROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG study by Avcı, Okan, İriağaç, Yakup, Çavdar, Eyyüp, Karaboyun, Kubilay, Araz, Murat, Şakalar, Teoman, Değerli, Ezgi, Özdemir, Özlem, İnal, Ali, Ocak, Birol, Ürün, Müslih, Sakin, Abdullah, Yıldız Tacar, Seher, Koçak, Mehmet Zahid, Demir, Hacer, Özer, Özden, Tanrıkulu Şimşek, Eda, Ersoy, Mustafa, Karakaş, Yusuf, Arıkan, Rukiye, Eşbah, Onur, Ön, Sercan, Şenocak Taşçı, Elif, Molinas Mandel, Nil, Türker, Sema, Kaçan, Turgut, Yıldırım, Hasan Çağrı, Alan, Özkan, Akbaş, Sinem, İpek Deniz, Gülhan, Aydın İsak, Özlem, Taşkaynatan, Halil, Şeber, Erdoğan Selçuk

“…In this study, the toxicities and management of palbociclib and ribociclib in older patients (≥65 years) with metastatic breast cancer patients were…”
Get full text

Time to Castration Resistance as a Predictor of Response to Docetaxel in Metastatic Castration Resistance in Prostate Cancer by Gulturk, Ilkay, Erdal, Gulcin Sahingoz, Sonmezoz, Gulru Birce, Yilmaz, Mesut, Tacar, Seher Yildiz, Ozmen, Aykut, Ozyukseler, Deniz Tataroglu, Dulgar, Ozgecan, Cil, Ibrahim, Tural, Deniz

“…Introduction: For metastatic prostate cancer (PC), androgen deprivation therapy (ADT) is the primary treatment option. Most patients develop resistance, after…”
Get full text

Next generation sequencing analysis of BRCA1 and BRCA2 identifies novel variations in breast cancer by Yildiz Tacar, Seher, Bozgeyik, Esra, Seber, Erdogan Selcuk, Yetisyigit, Tarkan, Tozkir, Hilmi, Avci, Okan, Arslan, Ahmet

“…Mutations in two major breast cancer susceptibility genes, BRCA1 and BRCA2, have been identified to be the most important predisposing factors for the…”
Get full text

Nivolumab induced hypophysitis in an advanced RCC patient by Korkmaz Yilmaz, Merve, Gulturk, Ilkay, Tacar, Seher Yildiz, Yilmaz, Mesut

“…Introduction Immune checkpoint inhibitors (ICIs) are being commonly used to treat solid tumours such as renal cell carcinoma. Hypophysitis is an acute or…”
Get full text

Prosnostic Significance of Prognostic Nutrition Index in Metastatic Renal Cell Carcinoma Patients Treated with Tyrosine Kinase Inhibitors by TACAR, Seher Yıldız, YILMAZ, Mesut, GÜLTÜRK, İlkay, TURAL, Deniz

“…Aim:The purpose of this study was to investigate the prognostic role of pretreatment Prognostic Nutritional Index (PNI) in metastatic renal cell carcinoma…”
Get full text

Can Cytoreductive Nephrectomy Improve Outcomes of Nivolumab Treatment in Patients with Metastatic Clear-Cell Renal Carcinoma? by Ocak, Birol, Sahin, Ahmet Bilgehan, Ertürk, Ismail, Korkmaz, Mustafa, Erdem, Dilek, Cakıroglu, Umut, Karaca, Mustafa, Dirican, Ahmet, Olmez, Omer Fatih, Goktas Aydın, Sabin, Gökyer, Ali, Kücükarda, Ahmet, Gülmez, Ahmet, Yumuk, Perran Fulden, Demircan, Nazim Can, Oyman, Abdilkerim, Sakalar, Teoman, Karatas, Fatih, Demir, Hacer, Yasin, Ayse Irem, Deligonul, Adem, Dakiki, Bahar, Goktug, Mehmet Refik, Avcı, Okan, Tacar, Seher Yildiz, Turhal, Nazım Serdar, Deniz, Gülhan Ipek, Kacan, Turgut, Cubukcu, Erdem, Evrensel, Türkkan

“…This study aimed to investigate the effect of cytoreductive nephrectomy (CN) on the survival outcomes of nivolumab used as a subsequent therapy after the…”
Get full text

Alectinib-induced Non-immune Hemolytic Anemia due to Erythrocyte Membrane Alterations: A Retrospective Evaluation by Gültürk, Emine, Akkaya, Eyyüp, Kapucu, Korhan, Tacar, Seher Yıldız, Akdağ, Goncagül, Kahraman Diril, Merve, Hindilerden, Fehmi

Get full text

Crizotinib for c-MET–amplified advanced NSCLC: a single-center experience by Tacar, Seher Yildiz, Yilmaz, Mesut, Oz, Buge, Tural, Deniz

“…Introduction: Lung cancer is the most common cause of cancer-related death in the world. Changes in the treatment of metastatic lung cancer in recent years…”
Get full text

Patient preferences for use of archived biospecimens in Turkey by Kubilay Tolunay, Pinar, Erol, Cihan, Kahraman, Seda, Tacar, Seher Yildiz, Özcan, Erkan, Basal, Fatma Bugdayci, Köse, Fatih, Sendur, Mehmet A.N., Tural, Deniz, Cicin, Irfan, Oksuzoglu, Berna, Ürün, Yüksel

“…e18904 Background: In the era of precision medicine translational research biospecimen collection and data sharing is increasingly needed. Ethical challenges…”
Get full text

Awareness and perceptions of clinical trials in patients with cancer and their families in Turkey by Kubilay, Pinar, Erol, Cihan, Kahraman, Seda, Tacar, Seher Yildiz, Özcan, Erkan, Basal, Fatma Bugdayci, Köse, Fatih, Sendur, Mehmet Ali Nahit, Tural, Deniz, Cicin, Irfan, Oksuzoglu, Berna, Ürün, Yüksel

“…e18780 Background: Patient preference plays an important role in enrolling in clinical trials. We conducted this study to understand the perceptions knowledge…”
Get full text

Alectinib-induced Non-immune Hemolytic Anemia due to Erythrocyte Membrane Alterations: A Retrospective Evaluation/Alektinib Iliskili Eritrosit Membran Degisikliklerine Bagli Immun Olmayan Hemolitik Anemi: Retrospektif Bir Degerlendirme by Gulturk, Emine, Akkaya, Eyyup, Kapucu, Korhan, Tacar, Seher Yildiz, Akdag, Goncagul, Diril, Merve Kahraman, Hindilerden, Fehmi

“…Objective: The purpose of this study was to evaluate changes in erythrocyte morphology associated with alectinib and resulting hemolytic anemia. Methods: This…”
Get full text

Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study by Tacar, Seher Yildiz, Selcukbiricik, Fatih, Yilmaz, Mesut, Erturk, Kayhan, Murat Sarici, Ahmet, Gulturk, Ilkay, Ayhan, Murat, Tural, Deniz

“…Systemic treatment options with proven efficacy for the treatment of metastatic uveal melanoma are limited. In this study, we aimed to evaluate the efficacy of…”
Get full text

Breast cancer in young and very young women; Is age related to outcome? by Avci, Okan, Tacar, Seher, Seber, Erdogan, Yetisyigit, Tarkan

“…Background: Breast cancer in young women is associated with aggressive biology. We analyzed histopathological and clinical properties of breast cancer patients…”
Get full text

Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study by Tacar, Seher Yildiz, Selcukbiricik, Fatih, Yilmaz, Mesut, Erturk, Kayhan, Murat Sarici, Ahmet, Gulturk, Ilkay, Ayhan, Murat, Tural, Deniz

“…Systemic treatment options with proven efficacy for the treatment of metastatic uveal melanoma are limited. In this study, we aimed to evaluate the efficacy of…”
Get full text

With metastatic colorectal cancer: A single center experience use of monoclonal antibodies (Bevacizumab, Cetuximab, and Panitumumab) in patients by GÜLTÜRK, İlkay, ŞAHİNGÖZ ERDAL, Gülçin, ÖZMEN, Aykut, YILDIZ TACAR, Seher, YILMAZ, Mesut, TURAL, Deniz

Get full text

Alectinib-induced Non-immune Hemolytic Anemia due to Erythrocyte Membrane Alterations: A Retrospective Evaluation by Gültürk, Emine, Akkaya, Eyyüp, Kapucu, Korhan, Tacar, Seher Yıldız, Akdağ, Goncagül, Kahraman Diril, Merve, Hindilerden, Fehmi

Get full text

Decrease in estimated glomerular filtration rates in non-small cell lung cancer patients treated with crizotinib by Iriagac, Yakup, Cavdar, Eyyup, Karaboyun, Kubilay, Tacar, Seher Yildiz, Akkoc Mustafayev, Fatma Nihan, Celik, Emir, Avci, Okan, Okutur, Sadi Kerem, Koral, Lokman, Demirci, Nebi Serkan, Ozgun, Alpaslan, Seber, Erdogan Selcuk

“…Crizotinib is a tyrosine kinase inhibitor used in patients with non-small cell lung cancer, and there are uncertainties about its effect on kidney function. In…”
Get full text

Thirty-day mortality rates after immunotherapy initiation by Sütcüoğlu, Osman, İlhan, Ayşegül, Tacar, Seher Yıldız, Güven, Deniz Can, Uçar, Gökhan, Karadurmuş, Nuri, Yıldız, Fatih, Eraslan, Emrah, Uncu, Doğan, Tural, Deniz, Üner, Aytuğ, Günel, Nazan, Özdemir, Nuriye, Kılıçkap, Saadettin, Öksüzoğlu, Ömür Berna, Özet, Ahmet, Yazıcı, Ozan

“…The aim of this study was to determine the cause of death in patients who died within 30 days after the first dose of immunotherapy. The data of 1432 patients…”
Get full text